MG-T-19
Based on 1 Customer Validation
MG-T-19 is a potent small-molecule inhibitor targeting human TIM-3. MG-T-19 blocks the interactions between TIM-3 and its ligands such as phosphatidylserine, CEACAM1 and Galectin-9. MG-T-19 promotes the secretion of TNF-α and IFN-γ by peripheral blood mononuclear cells, and significantly enhances their ability to inhibit cancer cell proliferation. MG-T-19 can be used in studies related to acute myeloid leukemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.34%
- CAS No.: 328540-44-9
- Formule: C18H8Br2ClF3N4O2S
- Masse moléculaire:596.60
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Pyroptosis Compound Library
HY-L059
-
Angiogenesis-Related Compound Library
HY-L088
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Immunopotentiator Compound Library
HY-L172
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
MG-T-19 (2.5 μM) significantly inhibits the interactions of human TIM-3 with PtdSer, CEACAM1, and Gal-9 in cell-free and cell-based ligand binding assays[1].
MG-T-19 (2.5 μM; 48 h) pretreatment of healthy donor PBMCs increases TNF-α and IFN-γ production following stimulation[1].
MG-T-19 (2.5 μM; 6 days) incubation of Kasumi-1 acute myelogenous leukemia cells with healthy donor PBMCs significantly reduces Kasumi-1 cell proliferation[1].
MG-T-19 binds to purified human TIM-3 with a Kd of 0.26 μM and inhibits TIM-3 interactions with its ligands PtdSer, CEACAM-1, and galectin-9[2].
MG-T-19 enhances TNF-α and IFN-γ secretion by healthy donor peripheral blood mononuclear cells and boosts inhibition of Kasumi-1 cell proliferation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Kasumi-1 acute myelogenous leukemia cells, peripheral blood mononuclear cells (PBMCs) from healthy donors
-
Concentration:2.5 μM
-
Incubation Time:6 days; 16 h (H3 thymidine labeling)
-
Result:Augmented the capacity of PBMCs to impede the proliferation of Kasumi-1 cells, resulting in significantly reduced H3 thymidine uptake compared to coculture controls.
Chemical Information
-
CAS No. 328540-44-9
-
Appearance Solid
-
Masse moléculaire 596.60
-
Formule C18H8Br2ClF3N4O2S
-
Color Light yellow to yellow
-
SMILES
OC1=C(NC(C2=NN3C(N=C(C4=CC(Br)=CS4)C=C3C(F)(F)F)=C2Br)=O)C=C(Cl)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 14.29 mg/mL (23.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Abdel-Rahman SA, et al. Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints. Science advances. 2024 Oct 18;10(42):eadq5540. [Content Brief]
[2]. Wang L, et al. TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy. Journal of medicinal chemistry. 2025 Dec 25;68(24):25754-25771. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6762 mL | 8.3808 mL | 16.7617 mL | 41.9041 mL |
| 5 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL | 8.3808 mL | |
| 10 mM | 0.1676 mL | 0.8381 mL | 1.6762 mL | 4.1904 mL | |
| 15 mM | 0.1117 mL | 0.5587 mL | 1.1174 mL | 2.7936 mL | |
| 20 mM | 0.0838 mL | 0.4190 mL | 0.8381 mL | 2.0952 mL |
MG-T-19 Related Classifications
HY-159884 Related Classifications
Powered by Bioz